Abstract
This descriptive study used the Japanese spontaneous reporting data to investigate the time taken (TTILD) to development of interstitial lung disease (ILD) after initiation of chemotherapy and the death rates attributed in part to post-chemotherapy ILD (i.e., DR) for anticancer drugs. We evaluated TTILD and DR endpoints for 36 anticancer drugs, which are widely used for treating 11 solid and 3 hematological cancers, and are suspected of causing ILD, by using 8- year spontaneous reporting data recording for 2,553 patients in the reporting system of the relevant Japanese regulatory agency. The median TTILD and overall DR attributable to post-chemotherapy ILD for the drugs were 1.8 months and 29%, respectively. For most drugs, the median TTILDs were between 1 to 4 months, and the DRs attributable to postchemotherapy ILD were <40%; however, TTILDs were as long as 4 to 6 months and DRs attributable to postchemotherapy ILD were ≥40% for several other drugs. Of the 36 drugs, we identified those that may trigger postchemotherapy late-onset ILDs or result in high DRs. The anticancer drugs that may have triggered late-onset ILDs were defined as those that caused ILD development after approximately 4 months from the initial drug administration.
Keywords: Adverse drug-reaction reporting, anticancer drug, epidemiology, interstitial lung disease, post-marketing surveillance, spontaneous report.
Current Drug Safety
Title:A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan
Volume: 9 Issue: 3
Author(s): Akihiro Hirakawa, Kan Yonemori, Yachiyo Kuwatsuka, Makoto Kodaira, Harukaze Yamamoto, Mayu Yunokawa, Akinobu Hamada, Chikako Shimizu, Kenji Tamura, Akihiko Gemma and Yasuhiro Fujiwara
Affiliation:
Keywords: Adverse drug-reaction reporting, anticancer drug, epidemiology, interstitial lung disease, post-marketing surveillance, spontaneous report.
Abstract: This descriptive study used the Japanese spontaneous reporting data to investigate the time taken (TTILD) to development of interstitial lung disease (ILD) after initiation of chemotherapy and the death rates attributed in part to post-chemotherapy ILD (i.e., DR) for anticancer drugs. We evaluated TTILD and DR endpoints for 36 anticancer drugs, which are widely used for treating 11 solid and 3 hematological cancers, and are suspected of causing ILD, by using 8- year spontaneous reporting data recording for 2,553 patients in the reporting system of the relevant Japanese regulatory agency. The median TTILD and overall DR attributable to post-chemotherapy ILD for the drugs were 1.8 months and 29%, respectively. For most drugs, the median TTILDs were between 1 to 4 months, and the DRs attributable to postchemotherapy ILD were <40%; however, TTILDs were as long as 4 to 6 months and DRs attributable to postchemotherapy ILD were ≥40% for several other drugs. Of the 36 drugs, we identified those that may trigger postchemotherapy late-onset ILDs or result in high DRs. The anticancer drugs that may have triggered late-onset ILDs were defined as those that caused ILD development after approximately 4 months from the initial drug administration.
Export Options
About this article
Cite this article as:
Hirakawa Akihiro, Yonemori Kan, Kuwatsuka Yachiyo, Kodaira Makoto, Yamamoto Harukaze, Yunokawa Mayu, Hamada Akinobu, Shimizu Chikako, Tamura Kenji, Gemma Akihiko and Fujiwara Yasuhiro, A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan, Current Drug Safety 2014; 9 (3) . https://dx.doi.org/10.2174/1574886309666140601205940
DOI https://dx.doi.org/10.2174/1574886309666140601205940 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Safety of the Temozolomide in Patients with Malignant Glioma
Current Drug Safety Bioactive Compounds Containing Benzoxadiazole, Benzothiadiazole, Benzotriazole
Current Bioactive Compounds Fabrication and Physicochemical and Medicinal Characterization of Nano Traditional Chinese Medicine
Recent Patents on Engineering Melanoma and Epigenetic Treatment: Past and Future
Anti-Cancer Agents in Medicinal Chemistry A New 4-phenyl-1,8-naphthyridine Derivative Affects Carcinoma Cell Proliferation by Impairing Cell Cycle Progression and Inducing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Diagnosis and Therapy of Primary Adrenal Insufficiency
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Origins and Consequences of AID Expression in Lymphoid Neoplasms
Current Immunology Reviews (Discontinued) Isoliquiritigenin Inhibits Proliferation and Induces Apoptosis via Alleviating Hypoxia and Reducing Glycolysis in Mouse Melanoma B16F10 Cells
Recent Patents on Anti-Cancer Drug Discovery The Role of Epidermal Growth Factor Receptor in the Management of Gastrointestinal Carcinomas: Present Status and Future Perspectives
Current Pharmaceutical Design Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Anti-Oxidative Polyphenolic Compounds of Cocoa
Current Pharmaceutical Biotechnology Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets Induced Pluripotent Stem Cells and Their Potential for Basic and Clinical Sciences
Current Cardiology Reviews pH-Dependent Behavior of Novel Gellan Beads Loaded with Naproxen
Current Drug Delivery Targeting EZH2 for Cancer Therapy: Progress and Perspective
Current Protein & Peptide Science Placental Drug Disposition and Its Clinical Implications
Current Drug Metabolism Regulative Roles of Ghrelin in Ingestive Behavior, Upper Gastrointestinal Motility, and Secretion
Current Nutrition & Food Science Recent Aspects of Osmotic Pump Systems: Functionalization, Clinical use and Advanced Imaging Technology
Current Drug Metabolism Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology